Adagene Inc-adr (ADAG)

$1.88

+0.08

(+4.44%)▲

Market is closed - opens 8 PM, 11 Dec 2023

Insights on Adagene Inc-adr

  • Vs SGEN

    In the last 1 year, Seagen, Inc. has given 76.6% return, outperforming this stock by 37.3%

Performance

  • $1.78
    $1.90
    $1.88
    downward going graph

    5.32%

    Downside

    Day's Volatility :6.32%

    Upside

    1.05%

    downward going graph
  • $1.09
    $2.10
    $1.88
    downward going graph

    42.02%

    Downside

    52 Weeks Volatility :48.1%

    Upside

    10.48%

    downward going graph

Returns

PeriodAdagene Inc-adrSector (Health Care)Index (Russel 2000)
3 Months
30.56%
-0.7%
0.0%
6 Months
51.61%
1.3%
0.0%
1 Year
43.51%
-4.3%
-1.5%
3 Years
-86.74%
18.3%
-7.5%

Highlights

Market Capitalization
70.8M
Book Value
$1.89
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.86
Wall Street Target Price
13.77
Profit Margin
-160.77%
Operating Margin TTM
-29.19%
Return On Assets TTM
-16.29%
Return On Equity TTM
-37.28%
Revenue TTM
22.7M
Revenue Per Share TTM
0.52
Quarterly Revenue Growth YOY
340.9%
Gross Profit TTM
10.2M
EBITDA
-39.3M
Diluted Eps TTM
-0.86
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.65
EPS Estimate Next Year
-2.33
EPS Estimate Current Quarter
-0.38
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Adagene Inc-adr(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 632.45%

Current $1.88
Target $13.77

Company Financials

FY18Y/Y Change
Revenue
1.5M
-
Net Income
-14.7M
-
Net Profit Margin
-974.03%
-
FY19Y/Y Change
Revenue
480.0K
↓ 68.24%
Net Income
-17.3M
↑ 17.49%
Net Profit Margin
-3.6K%
↓ 2628.86%
FY20Y/Y Change
Revenue
480.0K
↑ 0.0%
Net Income
-16.4M
↓ 4.96%
Net Profit Margin
-3.4K%
↑ 178.83%
FY21Y/Y Change
Revenue
10.2M
↑ 2019.85%
Net Income
-73.2M
↑ 345.24%
Net Profit Margin
-719.18%
↑ 2704.88%
FY22Y/Y Change
Revenue
9.3M
↓ 8.67%
Net Income
-80.0M
↑ 9.28%
Net Profit Margin
-860.59%
↓ 141.41%
Q1 FY22Q/Q Change
Revenue
9.3M
-
Net Income
-42.7M
-
Net Profit Margin
-458.43%
-
Q1 FY23Q/Q Change
Revenue
8.4M
-
Net Income
-51.1M
-
Net Profit Margin
-607.32%
-
FY18Y/Y Change
Total Assets
54.4M
-
Total Liabilities
95.4M
-
FY19Y/Y Change
Total Assets
105.9M
↑ 94.59%
Total Liabilities
162.9M
↑ 70.68%
FY20Y/Y Change
Total Assets
84.3M
↓ 20.42%
Total Liabilities
173.7M
↑ 6.6%
FY21Y/Y Change
Total Assets
189.5M
↑ 124.9%
Total Liabilities
33.0M
↓ 81.02%
FY22Y/Y Change
Total Assets
152.4M
↓ 19.58%
Total Liabilities
69.3M
↑ 110.33%
Q1 FY22Q/Q Change
Total Assets
189.5M
↑ 0.0%
Total Liabilities
33.0M
↑ 0.0%
Q2 FY22Q/Q Change
Total Assets
178.6M
↓ 5.78%
Total Liabilities
65.9M
↑ 99.91%
Q4 FY22Q/Q Change
Total Assets
152.4M
-
Total Liabilities
69.3M
-
Q1 FY23Q/Q Change
Total Assets
152.4M
↑ 0.0%
Total Liabilities
69.3M
↑ 0.0%
Q2 FY23Q/Q Change
Total Assets
135.3M
↓ 11.22%
Total Liabilities
52.5M
↓ 24.24%
FY18Y/Y Change
Operating Cash Flow
-14.3M
-
Investing Cash Flow
-29.5M
-
Financing Cash Flow
51.1M
-
FY19Y/Y Change
Operating Cash Flow
-18.2M
↑ 27.26%
Investing Cash Flow
24.9M
↓ 184.23%
Financing Cash Flow
69.7M
↑ 36.5%
FY20Y/Y Change
Operating Cash Flow
-28.5M
↑ 57.16%
Investing Cash Flow
7.1M
↓ 71.55%
Financing Cash Flow
4.4M
↓ 93.63%
FY21Y/Y Change
Operating Cash Flow
-43.4M
↑ 52.17%
Investing Cash Flow
-2.5M
↓ 135.49%
Financing Cash Flow
145.4M
↑ 3174.27%
Q2 FY20Q/Q Change
Operating Cash Flow
-4.4M
↑ 0.0%
Investing Cash Flow
3.9M
↑ 0.0%
Financing Cash Flow
658.6K
↑ 0.0%
Q3 FY20Q/Q Change
Operating Cash Flow
-11.2M
↑ 153.91%
Investing Cash Flow
-335.7K
↓ 108.64%
Financing Cash Flow
1.8M
↑ 170.27%
Q4 FY20Q/Q Change
Operating Cash Flow
-8.5M
↓ 23.61%
Investing Cash Flow
-360.9K
↑ 7.49%
Financing Cash Flow
1.3M
↓ 24.59%

Technicals Summary

Sell

Neutral

Buy

Adagene Inc-adr is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Adagene Inc-adr
Adagene Inc-adr
38.24%
51.61%
43.51%
-86.74%
-86.74%
Moderna, Inc.
Moderna, Inc.
14.4%
-34.97%
-51.36%
-48.82%
345.97%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.45%
11.42%
13.15%
75.11%
123.61%
Novo Nordisk A/s
Novo Nordisk A/s
-4.11%
21.75%
48.89%
177.94%
327.61%
Seagen, Inc.
Seagen, Inc.
2.71%
11.07%
66.1%
14.54%
259.34%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-7.59%
2.8%
11.45%
56.2%
102.13%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Adagene Inc-adr
Adagene Inc-adr
NA
NA
NA
-0.65
-0.37
-0.16
0.0
1.89
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.72
-0.22
-0.07
0.0
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
23.18
23.18
1.75
42.5
0.17
0.09
0.01
234.47
Novo Nordisk A/s
Novo Nordisk A/s
41.18
41.18
4.02
2.67
0.89
0.22
0.01
20.77
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.38
26.38
0.5
15.04
0.23
0.14
0.0
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Adagene Inc-adr
Adagene Inc-adr
Buy
$70.8M
-86.74%
NA
-160.77%
Moderna, Inc.
Moderna, Inc.
Buy
$30.4B
345.97%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$88.5B
123.61%
23.18
30.47%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$459.0B
327.61%
41.18
35.11%
Seagen, Inc.
Seagen, Inc.
Hold
$40.2B
259.34%
NA
-32.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.5B
102.13%
26.38
35.94%

Institutional Holdings

  • SC China Holding Ltd

    3.06%

  • FMR Inc

    2.57%

  • Artal Group S A

    2.28%

  • General Atlantic Llc

    0.60%

  • BosValen Asset Management Ltd

    0.55%

  • Morgan Stanley - Brokerage Accounts

    0.24%

Corporate Announcements

  • Adagene Inc-adr Earnings

    Adagene Inc-adr’s price-to-earnings ratio stands at None

    Read More

Company Information

adagene was co-founded by two serial entrepreneurs to power antibody discovery. its aim is to become the leading player in antibody discovery and engineering. it has developed a proprietary dynamic precision library (dpl) and is showcasing the power of the library with a unique pipeline of innovative antibody therapeutics that is advancing into clinical trials. adagene previously has raised three series of financing with over $86 million. investors include f-prime capital (formerly fidelity biosciences), eight roads ventures china (formerly fidelity growth partners asia), 6 dimensions capital, gp healthcare capital, sequoia china, and new world tmt. for more information, please visit www.adagene.com.

Organization
Adagene Inc-adr
Employees
248
CEO
Dr. Peter P. Luo Ph.D.
Industry
Healthcare

Discover More

FAQs